U.S. Government to Grant Exclusive License for Vaccinia Virus Infections Treatment

Summary

The U.S. government has announced its intention to grant an exclusive, revocable license to Biofactura, Inc. for the development and use of monoclonal antibodies for the prevention and treatment of vaccinia virus infections and other orthopoxvirus infections, as outlined in two patents issued in 2002 and 2003.